Concepts (62)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 3 | 2022 | 332 | 0.720 |
Why?
|
| Antipsychotic Agents | 3 | 2022 | 380 | 0.720 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 286 | 0.680 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2021 | 148 | 0.650 |
Why?
|
| Psychotic Disorders | 2 | 2022 | 150 | 0.650 |
Why?
|
| Alcoholism | 1 | 2021 | 250 | 0.580 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 2017 | 5 | 0.560 |
Why?
|
| Risperidone | 1 | 2017 | 59 | 0.530 |
Why?
|
| Leuprolide | 1 | 2017 | 23 | 0.530 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2017 | 265 | 0.470 |
Why?
|
| Perceptual Disorders | 1 | 2015 | 4 | 0.460 |
Why?
|
| Hallucinogens | 1 | 2015 | 51 | 0.420 |
Why?
|
| Suicide | 1 | 2015 | 203 | 0.370 |
Why?
|
| Clozapine | 2 | 2022 | 26 | 0.370 |
Why?
|
| Narcotic Antagonists | 3 | 2021 | 110 | 0.360 |
Why?
|
| Electroconvulsive Therapy | 1 | 2011 | 82 | 0.340 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2011 | 128 | 0.310 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 327 | 0.300 |
Why?
|
| Analgesics, Opioid | 3 | 2021 | 471 | 0.270 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 763 | 0.220 |
Why?
|
| Lithium | 1 | 2024 | 71 | 0.210 |
Why?
|
| Caffeine | 1 | 2024 | 64 | 0.210 |
Why?
|
| Clonidine | 1 | 2021 | 33 | 0.170 |
Why?
|
| Methadone | 1 | 2021 | 124 | 0.170 |
Why?
|
| Veterans | 2 | 2022 | 1762 | 0.170 |
Why?
|
| Naloxone | 1 | 2020 | 48 | 0.170 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 113 | 0.160 |
Why?
|
| Drug Overdose | 1 | 2020 | 73 | 0.160 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 348 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1313 | 0.140 |
Why?
|
| Deprescriptions | 1 | 2017 | 10 | 0.140 |
Why?
|
| Acute Disease | 1 | 2021 | 1176 | 0.140 |
Why?
|
| Buprenorphine | 1 | 2019 | 102 | 0.140 |
Why?
|
| Subcutaneous Absorption | 1 | 2017 | 1 | 0.140 |
Why?
|
| Injections | 1 | 2017 | 153 | 0.140 |
Why?
|
| Aged | 4 | 2021 | 21386 | 0.130 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2017 | 98 | 0.130 |
Why?
|
| Humans | 11 | 2024 | 132373 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 651 | 0.090 |
Why?
|
| Alzheimer Disease | 1 | 2017 | 865 | 0.080 |
Why?
|
| Male | 5 | 2021 | 65072 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 1163 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 1577 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 672 | 0.070 |
Why?
|
| Risk Factors | 2 | 2020 | 10912 | 0.060 |
Why?
|
| Adult | 3 | 2021 | 31624 | 0.050 |
Why?
|
| Time Factors | 1 | 2011 | 6457 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2021 | 3710 | 0.040 |
Why?
|
| Suicide, Attempted | 1 | 2022 | 154 | 0.040 |
Why?
|
| United States | 3 | 2021 | 11631 | 0.040 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2019 | 23 | 0.040 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 71 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 460 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 694 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2020 | 513 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1230 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3422 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3745 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2020 | 17371 | 0.020 |
Why?
|
| Middle Aged | 2 | 2021 | 28895 | 0.020 |
Why?
|
| Female | 2 | 2021 | 70809 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 13020 | 0.010 |
Why?
|